Table 4.
Number and risk of neurological or autoimmune diseases among vaccinated cohort, stratified according to time since vaccination (≤6 weeks and >6 weeks) and vaccination in early and late phases of H1N1 vaccination campaign in Stockholm county, Sweden
| Outcome | ≤6 weeks after vaccination | >6 weeks after vaccination | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Early phase | Late phase | Early phase | Late phase | ||||||
| No of events | Hazard ratio* (95% CI) | No of events | Hazard ratio* (95% CI) | No of events | Hazard ratio* (95% CI) | No of events | Hazard ratio* (95% CI) | ||
| Neurological diseases: | |||||||||
| Bell’s palsy | 37 | 1.74 (1.16 to 2.59) | 21 | 1.02 (0.64 to 1.63) | 145 | 1.26 (1.01 to 1.57) | 130 | 1.16 (0.92 to 1.45) | |
| Guillain-Barré syndrome | 3 | 0.72 (0.19 to 2.66) | 3 | 1.92 (0.68 to 5.40) | 20 | 1.18 (0.64 to 2.17) | 13 | 0.92 (0.45 to 1.89) | |
| Multiple sclerosis | 12 | 1.35 (0.68 to 2.67) | 8 | 1.17 (0.53 to 2.57) | 36 | 0.95 (0.63 to 1.44) | 26 | 0.71 (0.45 to 1.12) | |
| Anaesthesia or hypoaesthesia | 8 | 1.61 (0.77 to 3.39) | 7 | 1.04 (0.43 to 2.55) | 50 | 1.15 (0.78 to 1.69) | 29 | 0.79 (0.50 to 1.24) | |
| Paraesthesia | 90 | 1.60 (1.25 to 2.05) | 55 | 1.23 (0.91 to 1.65) | 360 | 1.17 (1.02 to 1.34) | 245 | 0.87 (0.75 to 1.02) | |
| Polyneuropathy | 33 | 1.13 (0.75 to 1.70) | 28 | 1.79 (1.16 to 2.77) | 156 | 1.07 (0.86 to 1.34) | 90 | 1.01 (0.77 to 1.31) | |
| Narcolepsy | 1 | 0.98 (0.10 to 9.67) | 0 | — | 6 | 1.57 (0.45 to 5.50) | 5 | 1.42 (0.40 to 5.08) | |
| Narcolepsy (age ≤20 years) | 0 | — | 0 | — | 1 | 0.58 (0.05 to 6.72) | 5 | 2.25 (0.42 to 12.1) | |
| Autoimmune diseases: | |||||||||
| Rheumatoid arthritis | 40 | 1.08 (0.74 to 1.57) | 22 | 0.82 (0.52 to 1.28) | 212 | 1.00 (0.83 to 1.20) | 142 | 0.84 (0.68 to 1.04) | |
| Inflammatory bowel disease | 35 | 1.10 (0.74 to 1.63) | 27 | 1.00 (0.65 to 1.54) | 168 | 1.29 (1.06 to 1.58) | 130 | 1.01 (0.82 to 1.25) | |
| Type 1 diabetes† | 6 | 0.89 (0.31 to 2.52) | 7 | 1.18 (0.47 to 2.96) | 37 | 1.18 (0.72 to 1.94) | 39 | 0.85 (0.52 to 1.38) | |
*Adjusted for age, sex, socioeconomic status, and healthcare utilisation one year before start of follow-up.
†Population born 1990 or later.